Vialwirebiotech, curated
July 2, 2026, 11:30 PM
June 10, 2026
- 12:00 PM · BioWorld12:00 PMEurope’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis — BioWorld
- 12:00 PM · BioWorld12:00 PMParabilis takes top spot, pricing largest biopharma IPO at $670M — BioWorld
- 11:28 AM · BioPharma Dive11:28 AMSanofi stops immune drug trial in latest research setback — BioPharma Dive
- 11:21 AM · Pharmaceutical Executive11:21 AM<![CDATA[FDA Clears Every-8-Week Lebrikizumab Maintenance Dosing in Atopic Dermatitis]]> — Pharmaceutical Executive
- 10:47 AM · Drug Discovery World10:47 AMGLP-1 reduces liver fat by 63%, trial results show — Drug Discovery World
- 9:12 AM · BioPharma Dive9:12 AMAstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMSyntax Bio and Mayo Clinic partner in type 1 diabetes — BioWorld
- 9:00 AM · BioWorld9:00 AMSensorion selects SENS-601 as lead program for hearing loss — BioWorld
- 9:00 AM · BioWorld9:00 AMPhoremost unveils PMC-001 as lead program — BioWorld
- 9:00 AM · BioWorld9:00 AMAntengene’s ATG-201 gains IND clearance in China — BioWorld
- 6:09 AM · Pharmaceutical Technology6:09 AMAditxt and Ignite announce merger plans with strategic partner — Pharmaceutical Technology
- 4:25 AM · Pharmaceutical Technology4:25 AMMHRA to roll out new AI sandbox for medicines development — Pharmaceutical Technology
June 9, 2026
- 12:21 PM · BioPharma Dive12:21 PMMerck, Gilead report mixed outcomes in key lung cancer, HIV studies — BioPharma Dive
- 12:00 PM · BioWorld12:00 PM‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios — BioWorld
- 12:00 PM · BioWorld12:00 PMMed-tech IPO window holds with $1.51B raised through May in 2026 — BioWorld
- 12:00 PM · BioWorld12:00 PMJapan backs Oncolys virus therapy for esophageal cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMNMPA gives conditional nods to drugs by Lupeng, Vcare, Staidson — BioWorld
- 12:00 PM · BioWorld12:00 PMInnovent submits NDA for CLDN18.2 ADC for gastric cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMGLP-1s and more weigh in at ADA — BioWorld
- 11:50 AM · BioPharma Dive11:50 AMStealthy startup Treeline plans a reverse merger — BioPharma Dive
- 11:39 AM · Pharmaceutical Technology11:39 AMADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering — Pharmaceutical Technology
- 11:39 AM · Pharmaceutical Technology11:39 AMADA26: Early data for teplizumab demonstrates promise for slowing T1D progression — Pharmaceutical Technology
- 10:50 AM · STAT News
- 10:32 AM · Drug Discovery World10:32 AMCrystalys doses first patients in Phase II gout trial — Drug Discovery World
- 9:23 AM · Wired — Science9:23 AMLongevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss — Wired — Science
- 9:18 AM · PharmaVoice
- 9:00 AM · BioWorld9:00 AMModerna’s mRNA-4194 cleared for clinic for Lynch syndrome — BioWorld
- 9:00 AM · BioWorld9:00 AMCity Therapeutics advances RNAi pipeline with series B financing — BioWorld
- 9:00 AM · BioWorld9:00 AMFlobiotech and UCLA Health partner in neurodegeneration — BioWorld
- 9:00 AM · BioWorld9:00 AMGrant supports Harness Therapeutics’ Parkinson’s disease program — BioWorld
- 9:00 AM · BioWorld9:00 AMGen1e Lifesciences receives US FDA designations for GEn-1123 — BioWorld
- 9:00 AM · BioWorld9:00 AMEngitix seals GSK deal for targets to reverse liver fibrosis — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMVerdiva Bio presents preclinical data on obesity treatments — Drug Discovery World
- 5:05 AM · Pharmaceutical Technology5:05 AMPfizer’s Hympavzi secures FDA expanded indications for haemophilia — Pharmaceutical Technology
- 2:48 AM · STAT News2:48 AMSTAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B — STAT News